1. Introduction
The expression “Small-Fiber Neuropathy” (SFN) defines a wide group of disorders in which nerve fibers of a small caliber are preferentially affected. According to the classification based on dimension, small nerve fibers are defined as follows in the table below [ 1 ] ( Table 1 ):
Small nerve fibers serve somatic (pain and temperature sensation) and autonomic functions. Thus, their impairment can lead to sensory and/or vegetative symptoms [ 2 ]. Pain is often the cardinal sign of SFN, bearing neuropathic features such as paresthesias with a burning quality or “electric shock” or “painful cold”-like sensation; in some cases, such paresthesias can also be tingling, numbness, or “pins and needles”-like. Moreover, tactile allodynia and hyperesthesia are pathological phenomena specific to neuropathic pain. Impairment in thermoception can lead to hypoesthesia to cold and hot temperatures. Pruritus, both spontaneous and contact-evoked, is a sensory symptom mediated by C fibers expressing TRPV1 and TRPA receptors, which also mediate pain. Itch is indeed often present in disorders affecting small fibers and represents an important clue suggesting a neuropathic origin of pain [ 3 ].
Sensory symptoms present more frequently in a length-dependent fashion akin to large-fiber polyneuropathy, starting from the distal side of lower limbs and ascending. Still, non-length-dependent processes may occur, albeit less frequently, and may be more difficult to recognize and diagnose [ 4 , 5 ]. SFN can also be focal, affecting single body areas such as the cephalic region; burning mouth syndrome, characterized by chronic painful sensation in the oral area, has been suggested to be related to trigeminal SFN [ 6 ].
Autonomic impairment is less frequent but can affect the various domains of this system, such as the cardiovascular (orthostatic intolerance/hypotension), vasomotor (skin flushing), secretomotor (xerostomia, sialorrhea), gastrointestinal (constipation, diarrhea, gastroparesis), genitourinary (urinary retention/incontinence, erectile dysfunction), thermoregulatory (hypo/hyperthermia, heat/cold intolerance), and pupillomotor (myosis/mydriasis) domains [ 7 ].
SFN is a relatively recent pathological entity, as the identification and study of small nerve fiber structure and function had been challenging. Indeed, the impossibility of microscopically identifying epidermal fibers due to technical factors led to the theory that the epidermis did not possess nerve fibers, and it was only in the 1990s that intraepidermal small nerve fibers were demonstrated via staining with protein gene product 9.5 [ 8 ].
Diagnostic techniques assessing large nerve fiber integrity and function are now long-standing and firmly established (e.g., electroneuromyography, evoked potentials), while methods to assess small nerve fibers, such as skin biopsy and quantitative sensory testing (QST), are less diffuse. Nonetheless, their application has allowed for the creation of diagnostic criteria for SFN [ 2 , 7 ].
Diagnosis of SFN is still hindered by scarce acknowledgment by treating physicians and insufficient access to diagnostic techniques, which remain available only in specialized centers [ 9 ]. The aim of this narrative review is to provide a comprehensive picture of SFN while also focusing on the wide set of etiologies underlying SFN in order to promote recognition of SFN in non-specialized settings dealing with disorders associated with this entity.
2. Research Methods
The review is structured in different sections (Diagnosis, Etiologies, Treatment, and Conclusions). Due to the focus of the article on etiologies, a search strategy for the works to include has been employed: on the PubMed database, the terms “diabetes”, “metabolic”, “infection”, “autoimmune”, “vaccination”, “toxic”, “drug-induced”, “chemotherapy”, “inherited”, and “idiopathic” were searched with “AND “small-fiber neuropathy”” attached.
Criteria of inclusion were the use of the English language and research and review articles concerning the specific etiology of the search, thus excluding more general reviews. If studies dealt with neuropathies of both large and small nerve fibers, only data concerning pure SFN were valorized. The search was completed in the period between December 2024 and January 2025.
The research yielded 232 results for “diabetes”, 69 for “metabolic”, 44 for “infection”, 109 for “autoimmune”, 37 for “vaccination”, 28 for “toxic”, 3 for “drug-induced, 31 for “chemotherapy”, 33 for “inherited, and 131 for “idiopathic”. Of these, revision by the authors according to the selection criteria led to the identification of 40 articles, whose data are presented in the Section 4 .
3. Diagnosis
Precise diagnosis of SFN may be hindered by several issues. Patients may present with extensive pain-related symptoms, while objective clinical signs of small fiber impairment may be difficult to evaluate at the bedside without proper attention. Moreover, techniques assessing small fiber function and integrity are not readily available in most centers [ 9 ].
Nonetheless, aside from these more practical aspects, the lack of a true gold-standard diagnostic method for SFN is a key issue which has been extensively discussed and has significantly impacted on the development of diagnostic criteria [ 2 , 7 , 10 ].
Currently, a diagnosis of SFN can be made based on two different sets of criteria [ 2 , 11 ], as highlighted in Table 2 .
The Besta criteria were the first to be proposed: as discussed by the authors themselves in a reappraisal study a decade after their introduction, the combinatory approach of having two of three criteria met for diagnosis was devised to address the lack of a gold standard. In the same study, the Besta and NEURODIAB criteria have shown strong agreement when compared [ 7 ].
A clinical picture compatible with SFN is a fundamental aspect in both sets of criteria. More specifically, it has been shown that positivity to only diagnostic techniques (i.e., skin biopsy and QST) without a clinical picture, while compatible with an SFN diagnosis, is inferior to the presence of clinical signs and one positive technique. Furthermore, objective signs and not only subjective symptoms must be taken into account when defining a suggestive clinical picture, as symptoms alone are often not powerful enough to allow for diagnosis and can be unsubstantiated by techniques [ 7 ].
As discussed more extensively below, evaluation of autonomic impairment is often more difficult and, while still not incorporated, addition of diagnostic techniques for the autonomic nervous system in diagnostic criteria has been advocated [ 10 ].
3.1. History and Clinical Examination
Diagnosis of SFN requires a thorough process in which precise anamnestic data must be collected and a detailed clinical examination must be performed, also encompassing evaluation of sensory modalities of small nerve fibers [ 7 ].
Family history should be first collected with particular focus on members affected by pain or SFN-related phenomena such as erythromelalgia, suggesting a possible genetic cause of the disorder. Social and occupational history should determine exposure to offending agents such as alcohol. Past medical history should uncover previous exposure to neurotoxic drugs, such as chemotherapy, as well as disclosing disorders commonly associated with SFN, such as diabetes and glycemic intolerance or autoimmune disorders. Present history should then determine how the disorder presented and how it evolved. Care should be taken in exploring autonomic involvement via specific questions encompassing all domains [ 12 ].
Questionnaires to evaluate both pain and autonomic symptoms can be administered, including the “Douleur Neuropathique 4” (DN4) for the screening of neuropathic pain [ 13 ], the Small-Fiber Neuropathy—Symptom Inventory Questionnaire” (SFN-SIQ) [ 14 ] or the Composite Autonomic Symptom Score 31 (COMPASS-31) [ 15 ].
Clinical examination should first exclude the involvement of large nerve fibers, thus determining that no motor deficits and no impairment of sensation via the dorsal lemniscus system (e.g., vibration, position sense) are affected. Deep tendon reflexes should not be affected. Physical inspection of the patient may additionally provide valuable information about autonomic dysfunction (e.g., skin trophism and color) [ 16 ].
Small fiber function can be first assessed at bedside or in the outpatient setting by employing instruments assessing pain and temperature sensation, such as sterile pins or hot and cold objects. With enough patient cooperation, the area of sensory impairment can be mapped reliably. Specific phenomena such as tactile and mechanical allodynia can be assessed in affected areas [ 9 ].
3.2. Diagnostic Techniques
The following techniques are employed in clinical and research settings in order to support the diagnosis of SFN or study its pathogenetic mechanisms.
3.2.1. Skin Biopsy
Skin biopsy allows for the quantitative and qualitative evaluation of intraepidermal nerve fibers employing identification via protein gene product 9.5 (PGP 9.5) staining.
Subsequently, fibers are counted, and intraepidermal nerve fiber density (IENFD, i.e., fibers/mm) is calculated [ 17 ].
Two techniques of fiber staining are most commonly employed [ 18 ]: bright-field immunohistochemistry and indirect immunofluorescence. Different reference values for IENFD have been provided for both techniques [ 19 , 20 ], also adjusting for age and gender, although the exact cutoffs to define SFN have been debated [ 20 ].
As shown in Figure 1 , biopsy is most commonly performed at the lower limb, at a distal (leg, near malleoli) site.
Samples can also be collected at proximal (thigh, near the knee) sites, thus also allowing for the evaluation of the gradient of fiber loss. While reduced IENFD is the key required finding in SFN diagnosis, structural alterations of nerve fibers have long been appreciated in neuropathies, as well; abnormalities such as axonal swelling and increased branching are thought to suggest an early stage of nerve pathology, which can evolve into full-fledged neuropathy [ 21 , 22 ].
The autonomic nervous system, both with its sympathetic and parasympathetic branches, also innervates skin structures such as blood vessels, sweat glands, and the arrector pilorum muscle. Adrenergic and cholinergic nerve fibers make for a complex innervation picture that has not still been fully elucidated. As highlighted in a recent study [ 23 ], sympathetic adrenergic and cholinergic fibers are abundant in skin, while parasympathetic cholinergic fibers can also be found. Most importantly, these fibers express different sets of markers, which allow for the identification of adrenergic (e.g., tyrosine hydroxylase—TH—and dopamine beta-hydroxylase—DbH) and cholinergic (vesicular acetylcholine transporter—VACHT) function. While possible, autonomic profiling is still technically demanding and time-consuming; therefore, obtaining quantitative data from skin biopsy has still not become routine [ 23 ]. A limitation of skin biopsy in SFN is that it cannot assess the in vivo function of small fibers, which can be dysregulated in some forms of neuropathy, such as in the case of toxic SFN, in which noxious agents may interfere with ion channel function without altering fiber structure [ 24 ].
3.2.2. Quantitative Sensory Testing (QST)
Quantitative sensory testing (QST) refers to batteries of psychophysical testing using instruments specific for different sensory modalities with the aim of determining the sensory thresholds for such modalities. Thus, both large and small nerve fiber functions can be assessed, and a complete sensory profile can be provided [ 25 ].
The German Research Network on Neuropathic Pain (DFNS) has devised a standardized protocol with reference values, comprising 7 tests and 13 parameters, comprising cold and warm sensation, thermal pain thresholds, mechanical pain sensitivity, pinprick sensitivity, mechanical allodynia, and pain summation to repetitive pinprick stimuli [ 26 ]. The sensory threshold can be determined through different means: in the limits method, a continuous stimulus increasing or decreasing at a fixed rate is administered, and the patient signals when the specific sensation is felt; in the levels method, the stimulus is presented at a fixed value and time period, and the patient indicates whether it was felt, then leading to increases or decreases in the stimulus until a sensation threshold can be determined [ 25 ].
QST has been employed in studying SFN caused by different etiologies, such as diabetic [ 27 ] and Fabry disease [ 28 ], in which this technique determined a particularly altered cold sensation.
While theoretically providing quantitative data on sensory pathway function, QST still relies on full patient cooperation and the comprehension of testing.
3.2.3. Laser-Evoked Potentials
This subgroup of evoked potentials employs painful stimuli that elicit signals from the nociceptive pathways, thus also allowing for the study of small nerve function. Among these are laser-evoked potentials (LEPs) and contact-heat-evoked potentials (CHEPs) [ 29 ].
LEPs assess the status of the spinothalamic pathway through the administration of painful stimuli through infrared lasers. LEPs stand out as one of the most reliable techniques for the assessment of nociception, although the recording of C fibers is difficult and not possible from arms, allowing objective and reproducible evaluation of both the peripheral and central pain pathways [ 30 ].
3.2.4. Autonomic Testing
These include a range of different tests assessing the function of various autonomic domains. Cardiovascular testing evaluates how the autonomic nervous system exerts control over cardiovascular reflexes. Among such tests is tilt testing, in which the patient is strapped on a bed that is tilted to assess the baroreceptor reflex, and the Valsalva maneuver assessing the cardiovascular response when transient intra-abdominal pressure is applied. Such evaluation is particularly relevant when the patient refers symptoms that could be correlated to orthostatic intolerance (e.g., dizziness when standing up), which could be explained by orthostatic hypotension or tachycardia, as seen in postural orthostatic tachycardia syndrome (POTS) [ 31 ].
Other autonomic tests include sudomotor evaluation, which can employ different techniques such as the sympathetic skin response (SSR) and the quantitative sudomotor axon reflex testing (QSART). The SSR uses electrodes on the surface of hands and feet to record a low-frequency response to stimulation (electrical or via other means). The QSART evaluates instead the effect of acetylcholine iontophoresis into the skin, which causes both a direct sudomotor response of the specific area and an indirect response of neighboring regions [ 29 ].
3.2.5. Corneal Confocal Microscopy
The cornea is a densely innervated part of the eye, and its nerve fibers play a key role in protective mechanisms, such as tear secretion and the blink reflex [ 32 ].
Originally applied in corneal disorders, confocal microscopy of the cornea allows for quantitative and qualitative measurement of innervation. Its first application in the neurological field was in patients with diabetic polyneuropathy, where reduction in innervation preceded symptoms of impaired corneal sensitivity [ 33 ]. As highlighted in a review by Petropoulos et al. [ 34 ], corneal confocal microscopy has then been applied in the study of both large and small-fiber neuropathy from a wide range of causes, consistently showing abnormalities. Similarly to skin biopsy, altered innervation was also found in neurodegenerative disorders, such as amyotrophic lateral sclerosis [ 35 ] and stroke [ 36 ]. Thus, with the development of reference values, such a technique represents a promising non-invasive mean of both diagnostic and prognostic values in painful neuropathies, also comprising SFN.
3.2.6. Microneurography
Microneurography allows direct, in vivo characterization of unmyelinated, small fiber activity from peripheral nerves (typically peroneal) by the insertion of a tungsten needle into nerve fascicles. This technique has been widely employed for recording sympathetic outflow activity (either as skin sympathetic nerve activity—MSNA—or muscle sympathetic nerve activity—SSNA) both in physiological and pathological states, such as in patients presenting with dysautonomia [ 37 ]. Moreover, microneurographic recording of nociceptor activity from C fibers has also been a longstanding line of research [ 38 ]. In particular, microneurography has provided insight into pain-related phenomena such as hyperalgesia [ 39 ]. Thus, while not readily applicable to clinical practice, it represents a key technique for research applications.
4. Etiology
While SFN has been associated with a multitude of different disorders and pathological processes, it is estimated that 50% of cases remain idiopathic [ 9 ].
4.1. Metabolic
Diabetes mellitus, either type 1 or 2, is among the most widespread disorders in the world, causing significant morbidity and mortality due to multisystem involvement. This also includes the peripheral nervous system, as diabetes is associated with the development of different types of neuropathies. While length-dependent large-fiber polyneuropathy is most commonly encountered, isolated SFN is possible and thought to represent a precursor form of neuropathy ultimately leading to large-fiber neuropathy; autonomic involvement is also prominent in diabetic SFN [ 40 ].
While not fully elucidated, the pathophysiology of diabetic neuropathy is closely related to multisystem derangement induced by hyperglycemia, which, aside from oxidative stress, is at the base of multiple pathogenetic mechanisms, such as alterations of polyol or hexosamine metabolic pathways [ 41 ].
Even stages of prediabetes, characterized by impaired fasting glucose or impaired glucose tolerance, are associated with SFN [ 40 ].
Metabolic syndromes, particularly hypertriglyceridemia, have been associated with SFN [ 42 ].
Hypothyroidism may cause pain syndromes compatible with SFN, as determined by QST sensory thresholds [ 43 ].
Vitamin B12 deficiency is more commonly associated with the development of subacute combined degeneration of the spinal cord; however, a large cohort study has found its incidence to be higher in SFN patients when compared to the general population [ 44 ].
4.2. Infectious
Many infectious agents have been associated with SFN. Infection can cause direct involvement of the nervous system, as is the case for human immunodeficiency or herpes zoster viruses, or they can induce damage via other, multisystemic pathogenetic mechanisms, as is the case for hepatitis viruses leading to nerve damage via both vasculitic and metabolic impairment caused by hepatic impairment [ 45 ].
HIV infection, which causes diffuse involvement of both the central and peripheral nervous system, may cause sensory neuropathies with prominent pain, which has been shown to be related to IENFD loss [ 46 ]. Among the various hepatitis viruses, hepatitis C infection has been most commonly associated with the development of SFN [ 47 ]. Additionally, a case-control study has reported that neuropathic pain was a common complaint of patients with acute hepatitis E infection [ 48 ].
Lyme disease can lead to a chronic phase after treatment characterized by cognitive impairment and pain (post-treatment Lyme disease syndrome, PTLDS), which has been related to both somatic and autonomic SFN [ 49 ].
Herpes zoster is a disorder caused by reactivation of the varicella zoster virus, which can cause significant neuropathic pain after remission, known as post-herpetic neuralgia. Such a clinical picture has been shown to be caused by SFN [ 50 ]. Interestingly, pruritus is a commonly associated feature of herpes zoster. Among other herpes infections, Epstein–Barr virus (EBV) infection was described in a case of acute autonomic neuropathy [ 51 ].
Leprosy can cause different types of neuropathies, including clinical pictures dominated by neuropathic pain due to small-fiber neuropathy [ 52 ].
COVID infection can lead to a wide array of signs and symptoms in the chronic course (post-COVID), among which painful syndromes have been shown to be partly related to SFN [ 53 , 54 ].
Other agents described in case reports include hantavirus and Angiostrongylus cantonensis [ 55 , 56 ].
4.3. Immune-Mediated
Immune-mediated forms of SFN can be associated with immune activation in the context of autoimmune systemic or nervous system-specific disorders. Both large- and small-fiber neuropathy are possible in autoimmune disorders; painful syndromes can also be caused by autoimmune damage of dorsal root ganglia, which further complicates the clinical picture by causing non-length-dependent symptoms [ 57 ].
4.3.1. Autoimmune Systemic Disorders
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that can involve both the central (e.g., neuropsychiatric symptoms) and peripheral nervous system. SFN has been demonstrated in SLE patients presenting with neuropathic pain. Most interestingly, both length-dependent and non-length-dependent forms of SFN have been observed, the latter postulated to be due to dorsal root ganglion pathology [ 57 ].
Sjögren syndrome (SS), another multisystem disorder with a predilection for glandular tissue, has long been associated with the development of sensory neuropathies, typically large-fiber and axonal. However, pure SFN is possible and has been suggested to be associated with a distinct immunological profile [ 58 ].
In sarcoidosis, a granulomatous disorder, SFN has been estimated to be the most common neurological complication, associated with autonomic dysfunction [ 59 ].
4.3.2. Antibodies in SFN
As highlighted in a recent review [ 60 ], autoantibodies have been associated with functional small nerve fiber dysfunction and neuropathic pain and, in some cases, with SFN.
These include antibodies against trisulfated heparin disaccharide (TS-HDS) and fibroblast growth factor receptor-3 (FGFR-3), which have been associated with non-length-dependent SFN. Further research is needed to fully elucidate their role in the development of pain and nerve pathology [ 60 ].
4.4. Drug-Induced and Toxic
Chemotherapy-induced peripheral neurotoxicity (CIPN) is a known and possibly severe side effect with significant morbidity [ 61 ].
Platinum compounds are typical drugs causing CIPN, among which oxaliplatin stands out in that it causes acute cold-induced paresthesias, which have been related to its effect on Na + channels [ 62 ].
Bortezomib, used in the treatment of multiple myeloma, has been associated with somatic and autonomic length-dependent SFN [ 63 ].
Taxanes have also been shown to cause sensory neuropathy, only affecting small nerve fibers in some cases. More particularly, docetaxel can induce SFN, as demonstrated by skin biopsy and QST [ 64 ].
Metronidazole, an antibiotic, can induce both central and peripheral neurotoxic effects, also leading to painful SFN. Nitrofurantoin has shown similar effects on small nerve fibers [ 65 ].
Toxic agents such as alcohol cause both large- or predominantly small-fiber neuropathy [ 66 ].
4.5. Genetic
Genetic causes include syndromes in which SFN is the main presenting picture and inherited systemic disorders in which small fibers can be affected.
These disorders were recently reviewed [ 67 ]: in the former group are mutations of genes involving sodium ion channels, including SCN9A, SCN10A, and SCN11A. Pure SFN has been described in hereditary sensory and autonomic neuropathy types 1, 3, and 5 (HSAN1, HSAN3, HSAN5).
SCN9A encodes the voltage-gated sodium channel Nav1.7, which is extensively expressed in the peripheral (nociceptive and sympathetic fibers) as well as the central nervous system [ 68 ]. A wide range of pain-related disorders are associated with SCN9A mutations; primary erythromelalgia, characterized by episodes of intermittent burning pain and redness of extremities, was the first to be described and linked to missense mutations [ 69 ]. Shortly later, paroxysmal extreme pain disorder was associated with missense mutations, which prevent inactivation of Nav1.7 [ 70 ], while loss-of-function mutations were found in patients with congenital insensitivity to pain [ 71 ].
Subsequently, gain-of-function mutations were described in patients with SFN, also showing dorsal ganglion root hyperexcitability [ 72 ], and in patients with painful diabetic neuropathy [ 73 ].
SCN10A mutations, encoding Nav1.8, have been described in patients and families with painful and autonomic signs and symptoms [ 67 , 74 ], both as gain- and loss-of-function mutations.
SCN11 encodes Nav1.8, and mutations underlie hereditary sensory and autonomic neuropathy type 7 (HSAN7) [ 75 ]. SFN patients have also been found to present mutations of this gene [ 76 ].
Subsequently, there are hereditary disorders in which SFN can show somatic (e.g., Fabry disease) or autonomic (e.g., familial amyloidosis) predominance.
Fabry disease is caused by mutations of the α-galactosidase A (GLA) gene, which leads to multisystemic deposition of the glycolipid globotriaosylceramide. Pain and paresthesias affecting the extremities (acroparesthesias) are a predominant feature of the disease, occurring since childhood in classic forms of the disease. Extreme temperatures can exacerbate such symptoms. Involvement of the autonomic fibers of the gastrointestinal tract can lead to signs and symptoms that can be missed [ 77 ]. Painful signs and symptoms in Fabry disease are actually caused by a multifaceted set of pathophysiological mechanisms, first including dorsal root ganglion dysfunction, then small-fiber neuropathy, and central mechanisms [ 78 ].
Familial forms of amyloidosis, such as those caused by mutation of the transthyretin (TTR) gene, are characterized by autonomic SFN, as well as large-fiber involvement [ 67 ].
Ehlers–Danlos syndromes, a group of connective tissue disorders, are often characterized by pain, which was shown to be related to SFN [ 79 ].
4.6. Idiopathic
This is the most common etiology, but care must be taken not to overlook other potential causes of SFN. A key diagnostic aspect is differentiating such forms of SFN from other pain syndromes such as fibromyalgia, which in some subsets has shown alterations of intraepidermal innervation [ 80 ].
Relevant articles on the various etiologies of SFN are summarized in Table 3 .
5. Treatment
Treatment of SFN should focus on the management of symptoms negatively affecting quality of life.
As indicated in Table 4 , neuropathic pain can be treated by different classes of drugs, including gabapentinoids (pregabalin, gabapentin), serotonin and norepinephrine reuptake inhibitors (duloxetine, venlafaxine), and tricyclic antidepressants. Second-line approaches may include cannabinoids, topical capsaicin, and botulinum toxin type A ( Table 4 ).
Other approaches, such as cognitive-behavioral therapy, are possible and complementary [ 82 ].
The role of the Nav1.7, Nav1.8, and Nav1.9 channels in painful syndromes has suggested that targeted therapy could provide treatment specific to neuropathic pain; antagonist molecules have the challenge of being specific enough to these sodium channels without impairing the fundamental functions of other voltage-gated sodium channels; other approaches such as gene therapy are promising but demanding [ 83 ].
Similarly, autonomic symptoms can be managed with lifestyle measures (e.g., chewing gum for sialorrhea) or with specific therapy if severe (e.g., fludrocortisone for orthostatic hypotension).
6. Conclusions
SFN is a vast group of different disorders impacting small nerve fibers in possibly different ways. In this narrative review, articles have been selected and presented with attention to etiologies; this was because SFN can occur in a wide variety of non-neurological disorders, and its recognition should be improved in both neurologists and non-neurologists.
The results of the article selection have shown several isolated case reports or series linking SFN with different causes. While in some instances data are scant, acknowledgment of unusual causes can prompt the collection of larger and stronger data, which should entail precise identification of SFN cases. This can be achieved via a thorough neurological examination, with special focus on signs of somatic and autonomic impairment of small nerve fibers, and diagnostic techniques such as skin biopsy, which offers the advantage of providing quantitative and reproducible data on innervation.
Furthermore, higher recognition of SFN in long-known causes is also needed. For several systemic disorders, such as diabetes, amyloidosis, and Fabry disease, SFN can be thought of as a prodromal form of neuropathy and can represent such a warning signal of disease activity [ 40 ], and its identification could thus lead to the early treatment and prevention of higher, more widespread damage.
In conclusion, recognizing the many different etiologies of SFN, both common and rare, can lead to better symptom management and quality of life for patients.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Author Contributions
Conceptualization, A.F. and V.D.; review of the literature, A.F.; writing—original draft preparation, A.F.; writing—review and editing, V.D. and R.L. All authors have read and agreed to the published version of the manuscript.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
Not applicable.
Conflicts of Interest
The authors declare no conflicts of interest.
References
1. Kandel E.R. Koester J.D. Mack S.H. Siegelbaum S.A. Principles of Neural Science 6th ed. McGraw Hill New York, NY, USA 2021
2. Devigili G. Tugnoli V. Penza P. Camozzi F. Lombardi R. Melli G. Broglio L. Granieri E. Lauria G. The diagnostic criteria for small fibre neuropathy: From symptoms to neuropathology Brain J. Neurol. 2008 131 1912 1925 10.1093/brain/awn093 PMC2442424 18524793
3. Misery L. Brenaut E. Le Garrec R. Abasq C. Genestet S. Marcorelles P. Zagnoli F. Neuropathic pruritus Nat. Rev. Neurol. 2014 10 408 416 10.1038/nrneurol.2014.99 24912513
4. Gorson K.C. Herrmann D.N. Thiagarajan R. Brannagan T.H. Chin R.L. Kinsella L.J. Ropper A.H. Non-length dependent small fibre neuropathy/ganglionopathy J. Neurol. Neurosurg. Psychiatry 2008 79 163 169 10.1136/jnnp.2007.128801 17911181
5. Gemignani F. Giovanelli M. Vitetta F. Santilli D. Bellanova M.F. Brindani F. Marbini A. Non-length dependent small fiber neuropathy. a prospective case series J. Peripher. Nerv. Syst. 2010 15 57 62 10.1111/j.1529-8027.2010.00252.x 20433606
6. Lauria G. Majorana A. Borgna M. Lombardi R. Penza P. Padovani A. Sapelli P. Trigeminal small-fiber sensory neuropathy causes burning mouth syndrome Pain 2005 115 332 337 10.1016/j.pain.2005.03.028 15911160
7. Devigili G. Rinaldo S. Lombardi R. Cazzato D. Marchi M. Salvi E. Eleopra R. Lauria G. Diagnostic criteria for small fibre neuropathy in clinical practice and research Brain 2019 142 3728 3736 10.1093/brain/awz333 31665231 PMC6906595
8. Kennedy W.R. Wendelschafer-Crabb G. The innervation of human epidermis J. Neurol. Sci. 1993 115 184 190 10.1016/0022-510X(93)90223-L 8482979
9. Terkelsen A.J. Karlsson P. Lauria G. Freeman R. Finnerup N.B. Jensen T.S. The diagnostic challenge of small fibre neuropathy: Clinical presentations, evaluations, and causes Lancet Neurol. 2017 16 934 944 10.1016/S1474-4422(17)30329-0 29029847
10. Fabry V. Gerdelat A. Acket B. Cintas P. Rousseau V. Uro-Coste E. Evrard S.M. Pavy-Le Traon A. Which Method for Diagnosing Small Fiber Neuropathy? Front. Neurol. 2020 11 342 10.3389/fneur.2020.00342 32431663 PMC7214721
11. Tesfaye S. Boulton A.J.M. Dyck P.J. Freeman R. Horowitz M. Kempler P. Lauria G. Malik R.A. Spallone V. Vinik A. Diabetic neuropathies: Update on definitions, diagnostic criteria, estimation of severity, and treatments Diabetes Care 2010 33 2285 2293 10.2337/dc10-1303 20876709 PMC2945176
12. Cazzato D. Lauria G. Small fibre neuropathy Curr. Opin. Neurol. 2017 30 490 499 10.1097/WCO.0000000000000472 28665811
13. Bouhassira D. Attal N. Alchaar H. Boureau F. Brochet B. Bruxelle J. Cunin G. Fermanian J. Ginies P. Grun-Overdyking A. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4) Pain 2005 114 29 36 10.1016/j.pain.2004.12.010 15733628
14. Galosi E. Falco P. Di Pietro G. Leone C. Esposito N. De Stefano G. Di Stefano G. Truini A. The diagnostic accuracy of the small fiber neuropathy symptoms inventory questionnaire (SFN-SIQ) for identifying pure small fiber neuropathy J. Peripher. Nerv. Syst. 2022 27 283 290 10.1111/jns.12513 36175394 PMC10092576
15. Sletten D.M. Suarez G.A. Low P.A. Mandrekar J. Singer W. COMPASS 31: A refined and abbreviated Composite Autonomic Symptom Score Mayo Clin. Proc. 2012 87 1196 1201 10.1016/j.mayocp.2012.10.013 23218087 PMC3541923
16. Devigili G. Lombardi R. Lauria G. Cazzato D. The Evolving Landscape of Small Fiber Neuropathy Seminars in Neurology Thieme Medical Publishers, Inc. New York, NY, USA 2024 10.1055/s-0044-1791823 39433284
17. Raicher I. Ravagnani L.H.C. Correa S.G. Dobo C. Mangueira C.L.P. Macarenco R.S.e.S. Investigation of nerve fibers in the skin by biopsy: Technical aspects, indications, and contribution to diagnosis of small-fiber neuropathy Einstein 2022 20 eMD8044 10.31744/einstein_journal/2022MD8044 35830153 PMC9262281
18. Lauria G. Cornblath D.R. Johansson O. McArthur J.C. Mellgren S.I. Nolano M. Rosenberg N. Sommer C. EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy Eur. J. Neurol. 2005 12 747 758 10.1111/j.1468-1331.2005.01260.x 16190912
19. Lauria G. Bakkers M. Schmitz C. Lombardi R. Penza P. Devigili G. Smith A.G. Hsieh S. Mellgren S.I. Umapathi T. Intraepidermal nerve fiber density at the distal leg: A worldwide normative reference study J. Peripher. Nerv. Syst. 2010 15 202 207 10.1111/j.1529-8027.2010.00271.x 21040142
20. Provitera V. Gibbons C.H. Wendelschafer-Crabb G. Donadio V. Vitale D.F. Stancanelli A. Caporaso G. Liguori R. Wang N. Santoro L. A multi-center, multinational age- and gender-adjusted normative dataset for immunofluorescent intraepidermal nerve fiber density at the distal leg Eur. J. Neurol. 2016 23 333 338 10.1111/ene.12842 26493160
21. Kennedy W. Wendelschafer-Crabb G. Utility of Skin Biopsy in Diabetic Neuropathy Semin. Neurol. 1996 16 163 171 10.1055/s-2008-1040972 8987130
22. Lauria G. Holland N. Hauer P. Cornblath D.R. Griffin J.W. McArthur J.C. Epidermal innervation: Changes with aging, topographic location, and in sensory neuropathy J. Neurol. Sci. 1999 164 172 178 10.1016/S0022-510X(99)00063-5 10402030
23. Donadio V. Incensi A. Vacchiano V. Infante R. Magnani M. Liguori R. The autonomic innervation of hairy skin in humans: An in vivo confocal study Sci. Rep. 2019 9 16982 10.1038/s41598-019-53684-3 31740757 PMC6861237
24. Krøigård T. Svendsen T.K. Wirenfeldt M. Schrøder H.D. Qvortrup C. Pfeiffer P. Gaist D. Sindrup S.H. Oxaliplatin Neuropathy: Predictive Values of Skin Biopsy, QST and Nerve Conduction J. Neuromuscul. Dis. 2021 8 679 688 10.3233/JND-210630 33814460
25. Mücke M. Cuhls H. Radbruch L. Baron R. Maier C. Tölle T. Treede R.-D. Rolke R. Quantitative sensory testing (QST). English version Schmerz 2021 35 153 160 10.1007/s00482-015-0093-2 26826097
26. Rolke R. Baron R. Maier C. Tölle T.R. Treede D.R. Beyer A. Binder A. Birbaumer N. Birklein F. Bötefür I.C. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values Pain 2006 123 231 243 10.1016/j.pain.2006.01.041 16697110
27. Sveen K.A. Karimé B. Jørum E. Mellgren S.I. Fagerland M.W. Monnier V.M. Dahl-Jørgensen K. Hanssen K.F. Small- and Large-Fiber Neuropathy After 40 Years of Type 1 Diabetes Diabetes Care 2013 36 3712 3717 10.2337/dc13-0788 24026557 PMC3816884
28. Dütsch M. Marthol H. Stemper B. Brys M. Haendl T. Hilz M.J. Small Fiber Dysfunction Predominates in Fabry Neuropathy J. Clin. Neurophysiol. 2002 19 575 586 10.1097/00004691-200212000-00011 12488789
29. Truini A. Aleksovska K. Anderson C.C. Attal N. Baron R. Bennett D.L. Bouhassira D. Cruccu G. Eisenberg E. Enax-Krumova E. Joint European Academy of Neurology–European Pain Federation–Neuropathic Pain Special Interest Group of the International Association for the Study of Pain guidelines on neuropathic pain assessment Eur. J. Neurol. 2023 30 2177 2196 10.1111/ene.15831 37253688
30. Di Stefano G. La Cesa S. Leone C. Pepe A. Galosi E. Fiorelli M. Valeriani M. Lacerenza M. Pergolini M. Biasiotta A. Diagnostic accuracy of laser-evoked potentials in diabetic neuropathy Pain 2017 158 1100 1107 10.1097/j.pain.0000000000000889 28267059
31. Moak J.P. Ramwell C.B. Gordish-Dressman H. Sule S.D. Bettini E. Small fiber neuropathy in children, adolescents, and young adults with chronic orthostatic intolerance and postural orthostatic tachycardia syndrome: A retrospective study Auton. Neurosci. Basic Clin. 2024 253 103163 10.1016/j.autneu.2024.103163 38537312
32. Shaheen B.S. Bakir M. Jain S. Corneal nerves in health and disease Surv. Ophthalmol. 2014 59 263 285 10.1016/j.survophthal.2013.09.002 24461367 PMC4004679
33. Rosenberg M.E. Tervo T.M.T. Immonen I.J. Muller L.J. Gronhagen C. Vesaluoma M.H. Corneal Structure and Sensitivity in Type 1 Diabetes Mellitus Investig. Ophthalmol. Vis. Sci. 2000 41 2915 2921 10967045
34. Petropoulos I.N. Ponirakis G. Khan A. Gad H. Almuhannadi H. Brines M. Cerami A. Malik R.A. Corneal confocal microscopy: Ready for prime time Clin. Exp. Optom. 2020 103 265 277 10.1111/cxo.12887 30834591
35. Ferrari G. Grisan E. Scarpa F. Fazio R. Comola M. Quattrini A. Comi G. Rama P. Riva N. Corneal confocal microscopy reveals trigeminal small sensory fiber neuropathy in amyotrophic lateral sclerosis Front. Aging Neurosci. 2014 6 278 10.3389/fnagi.2014.00278 25360111 PMC4199282
36. Khan A. Akhtar N. Kamran S. Ponirakis G. Petropoulos I.N. Tunio N.A. Dargham S.R. Imam Y. Sartaj F. Parray A. Corneal Confocal Microscopy Detects Corneal Nerve Damage in Patients Admitted With Acute Ischemic Stroke Stroke 2017 48 3012 3018 10.1161/STROKEAHA.117.018289 29018135
37. Donadio V. Liguori R. Microneurographic recording from unmyelinated nerve fibers in neurological disorders: An update Clin. Neurophysiol. Off. J. Int. Fed. Clin. Neurophysiol. 2015 126 437 445 10.1016/j.clinph.2014.10.009 25457652
38. Torebjörk H.E. Hallin R.G. Identification of afferent C units in intact human skin nerves Brain Res. 1974 67 387 403 10.1016/0006-8993(74)90489-2 4470432
39. Serra J. Campero M. Bostock H. Ochoa J. Two types of C nociceptors in human skin and their behavior in areas of capsaicin-induced secondary hyperalgesia J. Neurophysiol. 2004 91 2770 2781 10.1152/jn.00565.2003 14762154
40. Sumner C.J. Sheth S. Griffin J.W. Cornblath D.R. Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance Neurology 2003 60 108 111 10.1212/WNL.60.1.108 12525727
41. Dewanjee S. Das S. Das A.K. Bhattacharjee N. Dihingia A. Dua T.K. Kalita J. Manna P. Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets Eur. J. Pharmacol. 2018 833 472 523 10.1016/j.ejphar.2018.06.034 29966615
42. Pittenger G.L. Mehrabyan A. Simmons K. Amandarice Dublin C. Barlow P. Vinik A.I. Small fiber neuropathy is associated with the metabolic syndrome Metab. Syndr. Relat. Disord. 2005 3 113 121 10.1089/met.2005.3.113 18370718
43. Ørstavik K. Norheim I. Jørum E. Pain and small-fiber neuropathy in patients with hypothyroidism Neurology 2006 67 786 791 10.1212/01.wnl.0000234035.13779.4a 16966538
44. Güneş H.N. Bekircan-Kurt C.E. Tan E. Erdem-Özdamar S. The histopathological evaluation of small fiber neuropathy in patients with vitamin B12 deficiency Acta Neurol. Belg. 2018 118 405 410 10.1007/s13760-017-0847-y 29052170
45. Chaudhry V. Corse A.M. O’Brian R. Cornblath D.R. Klein A.S. Thuluvath P.J. Autonomic and peripheral (sensorimotor) neuropathy in chronic liver disease: A clinical and electrophysiologic study Hepatol. Baltim. Md 1999 29 1698 1703 10.1002/hep.510290630 10347110
46. Boger M.S. Hulgan T. Haas D.W. Mitchell V. Smith A.G. Singleton J.R. Peltier A.C. Measures of small-fiber neuropathy in HIV infection Auton. Neurosci. Basic Clin. 2012 169 56 61 10.1016/j.autneu.2012.04.001 22542355 PMC3372978
47. Tharwa E.-S. Mohamed A. Elshazly H. Salama M. Youssef M.I. Bakeer M.S. Kamel S.Y. Abdelmageed S.M. Shabana H.S. Allam M.A. Sudomotor Changes in Hepatitis C Virus Infection with or without Diabetes Mellitus: A Pilot Study in Egyptian Patients Am. J. Trop. Med. Hyg. 2020 104 580 584 10.4269/ajtmh.20-0612 33245041 PMC7866365
48. Abravanel F. Pique J. Couturier E. Nicot F. Dimeglio C. Lhomme S. Chiabrando J. Saune K. Péron J.-M. Kamar N. Acute hepatitis E in French patients and neurological manifestations J. Infect. 2018 77 220 226 10.1016/j.jinf.2018.06.007 29966614
49. Novak P. Felsenstein D. Mao C. Octavien N.R. Zubcevik N. Association of small fiber neuropathy and post treatment Lyme disease syndrome PLoS ONE 2019 14 e0212222 10.1371/journal.pone.0212222 30753241 PMC6372188
50. Hashimoto T. Okuzawa M. Yamamoto M. Okuno S. Satoh T. Increased touch-evoked itch (punctate hyperknesis) in postherpetic itch: Implications of reduced intraepidermal nerve fibers representing small fiber neuropathy J. Dermatol. 2023 50 393 396 10.1111/1346-8138.16627 36353761
51. Bennett J.L. Mahalingam R. Wellish M.C. Gilden D.H. Epstein-Barr virus--associated acute autonomic neuropathy Ann. Neurol. 1996 40 453 455 10.1002/ana.410400316 8797536
52. Nascimento O.J.M. Leprosy neuropathy: Clinical presentations Arq. Neuropsiquiatr. 2013 71 661 666 10.1590/0004-282X20130146 24141500
53. Donadio V. Incensi A. Furia A. Parisini S. Colaci F. Giannoccaro M.P. Morelli L. Ricciardiello F. Di Stasi V. De Maria A. Small fiber neuropathy associated with COVID-19 infection and vaccination: A prospective case-control study Eur. J. Neurol. 2024 32 e16538 10.1111/ene.16538 39526678 PMC11625946
54. Falco P. Litewczuk D. Di Stefano G. Galosi E. Leone C. De Stefano G. Di Pietro G. Tramontana L. Ciardi M.R. Pasculli P. Small fibre neuropathy frequently underlies the painful long-COVID syndrome Pain 2024 165 2002 2010 10.1097/j.pain.0000000000003259 38723183
55. Anderson D. Beecher G. Power C. Bridgland L. Zochodne D.W. A neuropathic pain syndrome associated with hantavirus infection J. Neurovirol. 2017 23 919 921 10.1007/s13365-017-0576-2 28895058 PMC7095002
56. Yates J. Devere T. Sakurai-Burton S. Santi B. McAllister C. Frank K. Case Report: Angiostrongylus cantonensis Infection Presenting as Small Fiber Neuropathy Am. J. Trop. Med. Hyg. 2022 107 367 369 10.4269/ajtmh.22-0199 35895403 PMC9393434
57. Oomatia A. Fang H. Petri M. Birnbaum J. Peripheral neuropathies in systemic lupus erythematosus: Clinical features, disease associations, and immunologic characteristics evaluated over a twenty-five-year study period Arthritis Rheumatol. 2014 66 1000 1009 10.1002/art.38302 24757151
58. Liampas A. Parperis K. Erotocritou M.F. Nteveros A. Papadopoulou M. Moschovos C. Akil M. Coaccioli S. Hadjigeorgiou G.M. Hadjivassiliou M. Primary Sjögren syndrome-related peripheral neuropathy: A systematic review and meta-analysis Eur. J. Neurol. 2023 30 255 265 10.1111/ene.15555 36086910 PMC10087501
59. Gavrilova N. Starshinova A. Zinchenko Y. Kudlay D. Shapkina V. Malkova A. Belyaeva E. Pavlova M. Yablonskiy P. Shoenfeld Y. Small Fiber Neuropathy in Sarcoidosis Pathophysiol. Off. J. Int. Soc. Pathophysiol. 2021 28 544 550 10.3390/pathophysiology28040035 PMC8830461 35366250
60. Morelli L. Serra L. Ricciardiello F. Gligora I. Donadio V. Caprini M. Liguori R. Giannoccaro M.P. The role of antibodies in small fiber neuropathy: A review of currently available evidence Rev. Neurosci. 2024 35 877 893 10.1515/revneuro-2024-0027 38865989
61. Shah A. Hoffman E.M. Mauermann M.L. Loprinzi C.L. Windebank A.J. Klein C.J. Staff N.P. Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort J. Neurol. Neurosurg. Psychiatry 2018 89 636 641 10.1136/jnnp-2017-317215 29439162 PMC5970026
62. Park S.B. Lin C.S.-Y. Krishnan A.V. Goldstein D. Friedlander M.L. Kiernan M.C. Oxaliplatin-induced neurotoxicity: Changes in axonal excitability precede development of neuropathy Brain 2009 132 2712 2723 10.1093/brain/awp219 19745023
63. Giannoccaro M.P. Donadio V. Gomis Pèrez C. Borsini W. Di Stasi V. Liguori R. Somatic and autonomic small fiber neuropathy induced by bortezomib therapy: An immunofluorescence study Neurol. Sci. 2011 32 361 363 10.1007/s10072-010-0475-2 21290160
64. Krøigård T. Schrøder H.D. Qvortrup C. Eckhoff L. Pfeiffer P. Gaist D. Sindrup S.H. Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies Eur. J. Neurol. 2014 21 623 629 10.1111/ene.12353 24460946
65. Tan C.-H. Chen Y.-F. Chen C.-C. Chao C.-C. Liou H.-H. Hsieh S.-T. Painful neuropathy due to skin denervation after metronidazole-induced neurotoxicity J. Neurol. Neurosurg. Psychiatry 2011 82 462 466 10.1136/jnnp.2009.194118 20551481
66. Kokotis P. Papantoniou M. Schmelz M. Buntziouka C. Tzavellas E. Paparrigopoulos T. Pure small fiber neuropathy in alcohol dependency detected by skin biopsy Alcohol 2023 111 67 73 10.1016/j.alcohol.2023.05.006 37295567
67. Chan A.C.Y. Kumar S. Tan G. Wong H.Y. Ong J.J.Y. Chandra B. Huang H. Sharma V.K. Lai P.S. Expanding the genetic causes of small-fiber neuropathy: SCN genes and beyond Muscle Nerve 2023 67 259 271 10.1002/mus.27752 36448457
68. McDermott L.A. Weir G.A. Themistocleous A.C. Segerdahl A.R. Blesneac I. Baskozos G. Clark A.J. Millar V. Peck L.J. Ebner D. Defining the Functional Role of NaV1.7 in Human Nociception Neuron 2019 101 905 919.e8 10.1016/j.neuron.2019.01.047 30795902 PMC6424805
69. Yang Y. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia J. Med. Genet. 2004 41 171 174 10.1136/jmg.2003.012153 14985375 PMC1735695
70. Catterall W.A. Yu F.H. Painful Channels Neuron 2006 52 743 744 10.1016/j.neuron.2006.11.017 17145494
71. Cox J.J. Reimann F. Nicholas A.K. Thornton G. Roberts E. Springell K. Karbani G. Jafri H. Mannan J. Raashid Y. An SCN9A channelopathy causes congenital inability to experience pain Nature 2006 444 894 898 10.1038/nature05413 17167479 PMC7212082
72. Faber C.G. Hoeijmakers J.G.J. Ahn H. Cheng X. Han C. Choi J. Estacion M. Lauria G. Vanhoutte E.K. Gerrits M.M. Gain of function Na v 1.7 mutations in idiopathic small fiber neuropathy Ann. Neurol. 2012 71 26 39 10.1002/ana.22485 21698661
73. Blesneac I. Themistocleous A.C. Fratter C. Conrad L.J. Ramirez J.D. Cox J.J. Tesfaye S. Shillo P.R. Rice A.S.C. Tucker S.J. Rare NaV1.7 variants associated with painful diabetic peripheral neuropathy Pain 2018 159 469 480 10.1097/j.pain.0000000000001116 29176367 PMC5828379
74. Dabby R. Sadeh M. Broitman Y. Yosovich K. Dickman R. Leshinsky-Silver E. Painful small fiber neuropathy with gastroparesis: A new phenotype with a novel mutation in the SCN10A gene J. Clin. Neurosci. 2016 26 84 88 10.1016/j.jocn.2015.05.071 26711856
75. Leipold E. Liebmann L. Korenke G.C. Heinrich T. Gießelmann S. Baets J. Ebbinghaus M. Goral R.O. Stödberg T. Hennings J.C. A de novo gain-of-function mutation in SCN11A causes loss of pain perception Nat. Genet. 2013 45 1399 1404 10.1038/ng.2767 24036948
76. Eijkenboom I. Sopacua M. Hoeijmakers J.G.J. De Greef B.T.A. Lindsey P. Almomani R. Marchi M. Vanoevelen J. Smeets H.J.M. Waxman S.G. Yield of peripheral sodium channels gene screening in pure small fibre neuropathy J. Neurol. Neurosurg. Psychiatry 2019 90 342 352 10.1136/jnnp-2018-319042 30554136
77. Kummer K.K. Kalpachidou T. Kress M. Langeslag M. Signatures of Altered Gene Expression in Dorsal Root Ganglia of a Fabry Disease Mouse Model Front. Mol. Neurosci. 2017 10 449 10.3389/fnmol.2017.00449 29422837 PMC5788883
78. Burand A.J. Stucky C.L. Fabry disease pain: Patient and preclinical parallels Pain 2021 162 1305 1321 10.1097/j.pain.0000000000002152 33259456 PMC8054551
79. Cazzato D. Castori M. Lombardi R. Caravello F. Bella E.D. Petrucci A. Grammatico P. Dordoni C. Colombi M. Lauria G. Small fiber neuropathy is a common feature of Ehlers-Danlos syndromes Neurology 2016 87 155 159 10.1212/WNL.0000000000002847 27306637 PMC4940063
80. Giannoccaro M.P. Donadio V. Incensi A. Avoni P. Liguori R. Small nerve fiber involvement in patients referred for fibromyalgia Muscle Nerve 2014 49 757 759 10.1002/mus.24156 24469976
81. Moisset X. Bouhassira D. Avez Couturier J. Alchaar H. Conradi S. Delmotte M.H. Lanteri-Minet M. Lefaucheur J.P. Mick G. Piano V. Pharmacological and non-pharmacological treatments for neuropathic pain: Systematic review and French recommendations Rev. Neurol. 2020 176 325 352 10.1016/j.neurol.2020.01.361 32276788
82. Moisset X. Bouhassira D. Attal N. French guidelines for neuropathic pain: An update and commentary Rev. Neurol. 2021 177 834 837 10.1016/j.neurol.2021.07.004 34332778
83. Emery E.C. Luiz A.P. Wood J.N. Na v 1.7 and other voltage-gated sodium channels as drug targets for pain relief Expert Opin. Ther. Targets 2016 20 975 983 10.1517/14728222.2016.1162295 26941184 PMC4950419